In short
Clinical trials are investigating HYPOCHLOROUS ACID, given by inhalation, in healthy participants and people with chronic airway infections. These studies aim to assess safety, tolerability, and early signs of benefit. One trial also looks at whether treatment can reduce bacteria in sputum in patients with chronic airway infection.
Key points
- Clinical trials of HYPOCHLOROUS ACID are studying inhaled treatment for chronic airway infections. The trial includes a Phase 1 dose-escalation part in healthy participants to check safety and tolerability. It also includes a Phase 2a proof-of-concept part in people with CF, PCD, and NCFB to look for early signs of benefit. The main patient result being measured is the change in sputum bacterial density after treatment. The planned enrollment is 55 participants, and the study status is Authorised.
Trial overview
The available study is a single-centre clinical trial of HYPOCHLOROUS ACID given by inhalation as nebulised SS0331.
The study is designed to look first at safety and tolerability in healthy participants, and then at a preliminary effect in people with chronic airway infections.
The trial is authorised, is a Phase 1 study, and plans to enroll 55 participants.
Who can participate
The dose-escalation part of the trial includes healthy participants.
The later proof-of-concept part includes participants with chronic airway infections, including people with CF, PCD, and NCFB.
This means the study is not limited to one disease group, but it does focus on people who have long-term airway infection problems.
Study phases and design
The trial has a Phase 1 dose-escalation part, which means participants receive increasing doses so researchers can watch for safety issues and how well the treatment is tolerated.
It also has a Phase 2a proof-of-concept part, which is an early test to see whether the treatment may show a useful effect.
The study is described as interventional, meaning participants receive the study treatment rather than only being observed.
The brief summary says the inhaled nebulised SS0331 is administered three times daily for five days in the chronic airway infection group.
What is being measured
In the Phase 1 part, the main endpoint is the nature, incidence, and severity of adverse events.
Adverse events are unwanted medical problems that happen during a study, and researchers count how often they happen and how serious they are.
In the Phase 2a part, the main endpoint is the change from baseline in log10-transformed sputum density of bacteria after treatment.
Baseline means the starting point before treatment begins, and sputum density of bacteria means how much bacteria is found in mucus from the lungs.
The brief summary also states that the proof-of-concept goal is to look for a reduction in sputum bacterial density, measured as CFU/g, which is a way to count bacteria in a sample.
Patient groups and conditions
The condition being studied is chronic airway infections.
The patient group includes people with CF, PCD, and NCFB, which are all conditions linked to ongoing airway problems and repeated infections.
Healthy participants are also included, but only for the early safety and dose-escalation part of the trial.
This mix of participants helps researchers first check basic safety and then explore whether the treatment may help the target patient group.
Why this research matters
This trial is important because it does not only ask whether HYPOCHLOROUS ACID can be given safely by inhalation, but also whether it may lower bacterial levels in sputum.
That early signal of benefit is what makes the study a proof-of-concept trial.
For patients with long-term airway infections, studies like this are the first step toward learning whether a new inhaled treatment may help in real-world care.